CriMCE: A method to introduce and isolate precise marker-less edits via CRISPR-mediated cassette exchange

Ioanna Morianou¹, Andrea Crisanti^{1,2}, Tony Nolan³, Andrew M. Hammond^{1,4,5*}

*Corresponding author

Author Affiliations:

¹Department of Life Sciences, Imperial College London, London, UK ²Department of Molecular Medicine, University of Padova, Padua, Italy ³Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK ⁴Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA ⁵Biocentis, Ltd., London, UK

Running head:

CRISPR-based method for marker-less editing

Keywords:

CRISPR; genome editing; cassette exchange; marker-less edits; gene drive.

66

1

67 Abstract

69 The introduction of small, unmarked edits to the genome of insects is essential to study the

70 molecular underpinnings of important biological traits, such as resistance to insecticides and

71 genetic control strategies. Advances in CRISPR genome engineering have made this

possible, but prohibitively laborious for most laboratories due to low rates of editing and the

lack of a selectable marker. To facilitate the generation and isolation of precise marker-less
 edits we have developed a two-step method based upon CRISPR-mediated cassette

realising the developed a two-step method based upon CRISPR-mediated casselle
 exchange (CriMCE) of a marked placeholder for a variant of interest. This strategy can be

75 exchange (Childer) of a marked placeholder for a variant of interest. This strategy can be 76 used to introduce a wider range of potential edits compared to previous approaches whilst

77 consolidating the workflow. We present proof-of-principle that CriMCE is a powerful tool by

regineering three SNP variants into the genome of *Anopheles gambiae*, with 5-41x higher

79 rates of editing than homology-directed repair or prime editing.

122 Introduction

123

Small genetic changes, such as single nucleotide polymorphisms (SNPs), can give rise to

prominent phenotypes. For example, they are responsible for most genetic diseases in
 humans,¹ important agronomic traits in plants,² and insecticide resistance in insect vectors of
 disease.³

128

129 To study their molecular underpinning, it is essential to engineer small precise edits like

130 these in the laboratory,⁴ whilst excluding any transformation markers or gene editing debris

131 that could interfere with the observed phenotype. The introduction of such marker-less edits

- 132 has been facilitated by the discovery and expansion of CRISPR (clustered regularly
- 133 interspersed short palindromic repeats) technologies.
- 134

135 In its most common form, CRISPR genome editing comprises a Cas endonuclease, able to 136 catalyse a DNA double-stranded break (DSB); and a guide RNA (gRNA) that directs the Cas protein to its target sequence.⁵ Simple and complex edits can be introduced with precision at 137 138 a CRISPR-induced break by presenting a modified DNA template for homology directed 139 repair (HDR). Recently developed base editing and prime editing methods are less versatile 140 but work independently of the HDR pathway and can raise the efficiency of editing in species 141 where HDR is naturally low.⁶⁻¹⁰ Base editing can induce transition point mutations through a 142 Cas-deaminase fusion, whilst prime editing can introduce any point mutation or small indel 143 by employing a Cas-reverse transcriptase fusion and a prime editing gRNA (pegRNA) that functions as a template for repair.¹¹ Neither have been widely tested in insects, however 144

initial trials in *Drosophila* suggest that prime editing is no more efficient than HDR,¹² whilst
 base editing is effective but inherently imprecise.¹³

147

In insects, independent of the chosen technology, engineering small marker-less edits remains inefficient, with transformation rates rarely exceeding 5%.^{12,14,15} The lack of a molecular marker further hinders the process of identifying and isolating rare transformants, which becomes prohibitively laborious, relying upon large numbers of single crosses and molecular identification of variants. Although there has been an expansion in the methods to engineer marker-less edits, this has not been met with a similar level of expansion in

- 154 methods to isolate rare transformants.
- 155

We devised a two-step method to generate and facilitate the detection and isolation of precise marker-less edits, based upon <u>CRISPR-mediated cassette exchange</u> (CriMCE) of a marked placeholder for a variant of interest (**Figure 1A**). CriMCE relies upon the visual detection of an edit, through the loss of a marker (**Figure 1A**), which serves to enrich the pool of molecularly queried individuals for rare transformants, to reduce the labour and time required to isolate them (**Figure 1C**).

162

163 We demonstrate the value of CriMCE by deliberately introducing three SNP variants into the genome of the malaria mosquito, Anopheles gambiae, at the target site of a synthetic gene 164 drive in the *doublesex* gene.^{16,17} Gene drives are engineered selfish genetic elements that 165 show promise in controlling disease vector populations,^{16,18–20} but are susceptible to resistant 166 167 mutations arising at the gene drive target site, in the form of SNPs or small indels.^{21–23} For 168 vector control strategies, including insecticides and gene drive, it is becoming increasingly 169 important to anticipate the emergence of resistance and pre-emptively design contingency 170 plans. The SNP variant strains generated in this study will be useful in studying the potential 171 for resistance to gene drives targeting a highly conserved site on *doublesex* and will inform 172 implementation strategies.

173

We show that CriMCE is more efficient than methods previously employed to introduce small, unmarked edits,^{12,14,15} whilst retaining versatility that would allow the engineering of

176 more complex modifications as well (**Figure 1B**).

177 Materials and Methods

178

179 Molecular cloning of CRISPR plasmids

180181 We used Golden Gate cloning to insert a dual gRNA expression cassette into the p174

182 master vector,¹⁶ to generate CRISPR vectors p174102 and p17404 needed to catalyse

183 genomic cleavage for the insertion of a placeholder cassette and the variant of interest,

respectively. We first amplified a gRNA scaffold-U6 terminator-U6 promoter sequence, from

185 plasmid p131 using primers containing *Bsal* sites (underlined), and gRNA sequences 186 (capitals): Bsal-T1-U6-F

187 (gagggtctcatgctGTTTAACACAGGTCAAGCGGgttttagagctagaaatagcaagt) and Bsal-T3-U6-R

188 (gagggtctcaaaacCTCTGACGGGTGGTATTGCagcagagagcaactccatttcat), to add *doublesex* 189 targeting gRNAs onto p174 and Bsal-G1-U6-F

190 (gagggtctcatgctGGTTAATTCGAGCTCGCCCGgttttagagctagaaatagcaagt) and Bsal-G2-U6-

191 R (gagggtctcaaaacCAACTAGAATGCAGTGAAACagcagagagcaactccatttcat) to add

192 placeholder targeting gRNAs. The PCR products were inserted into p174, through

193 GoldenGate cloning, to create CRISPR vectors p174102 and p17404, containing a

194 *zpg::hCas9*, a *3xP3::DsRed::SV40* marker and U6-expressed *doublesex*-targeting gRNAs

195 (T1 and T3) or placeholder-targeting gRNAs (G1 and G3), respectively.

- 196
- 197 Molecular cloning of placeholder donor plasmid
- 198

199 A 3xP3::GFP::SV40 marker cassette was amplified from plasmid pK101,¹⁶ using primers

200 SgsI-3xP3-F (GGCGCGCCCCACAATGGTTAATTCGAGC) and SgsI-SV40-R

201 (GGCGCGCCAAGATACATTGATGAGTTTGGAC). Genomic DNA regions ~1.8 kb upstream

and downstream of the *doublesex* intron 4-exon 5 splice junction were amplified using primer
 pairs: 4050-KI-Gib1

207 (GAGCTCGAATTAACCATTGTGGGGCGCGCGCGTATCTTTGTATGTGGGTGTGTG) with 208 4050-KI-Gib4

209 (TCCACCTCACCCATGGGACCCACGCGTGGTGCGGGTCACCGAGATGTTC), to make up

210 the right and left homology arms, respectively, of the donor plasmid. To generate the

- 211 placeholder donor plasmid pHolder-dsx the three PCR products were combined with a
- 212 digested vector backbone containing a 3xP3::DsRed::SV40 marker cassette in a four-
- fragment Gibson assembly, so that the *dsx* homology arms flank the GFP placeholder
- 214 cassette.215

216 Molecular cloning of variant donor plasmids

217 1010

An intermediate plasmid (pVar-dsx) was Gibson assembled to contain the same vector

backbone and homology arms as for pHolder, and a sequence containing *Bsal* cloning sites,

- flanking the region of interest of an otherwise intact exon 5 (**Supplementary Figure 1A-C**).
- This allowed the Golden Gate cloning of annealed oligos containing three different

doublesex exon 5 variants: a $G \rightarrow A$ SNP (GTTTAACACAGGTCAAGCAGTGGT,

- chromosome 2, position 47,997,665), a C \rightarrow T SNP (GTTTAACACAGGTCAAGTGGTGGT, chromosome 2, position 47,997,666) and a G \rightarrow T SNP (GTTTAACACAGGTCAATCGGTGG.
- chromosome 2, position 47,997,666) and a $G \rightarrow T$ SNP (GTTTAACACAGGTCAA**T**CGGTGG, chromosome 2, position 47,997,667). The same plasmid, pVar-dsx, can be used to clone
- 226 and study more variants at the same target site in the future.
- 227

228 Embryo microinjections

229

Anopheles gambiae G3 strain mosquitoes were reared at 26±2°C and 65±10% relative

231 humidity and blood-fed on cow blood using Hemotek membrane feeders.¹⁸ Microinjections

- were performed on freshly laid embryos as previously described.²⁴ Each microinjected 232 233 plasmid was present in solution at 300 ng/µl.
- 234

235 To generate the placeholder strain, wild-type embryos were microinjected with the p174102 236 CRISPR plasmid and pHolder donor plasmid (Supplementary Figure 1D-E). In 237 transformants, this caused the excision of the coding sequence (CDS) of the female-specific 238 exon 5 of the doublesex gene and its replacement with a GFP marker cassette. All

- 239 microinjection survivors (G0) were crossed to wild-type mosquitoes and positive
- 240 transformants (G1) were identified through fluorescence microscopy, as GFP+.
- 241

242 To generate the SNP variant strains, placeholder homozygote males were crossed to 243 placeholder heterozygote females, distinguished using the COPAS fluorescence-based

- 244 larval sorter.²⁵ Their progeny was microinjected with the p174104 CRISPR plasmid and each 245 of the variant donor plasmids (pVar-dsxGA, pVar-dsxCT, pVar-dsxGT) (Supplementary
- 246 Figure 1D-E). In successful transformants, this caused the CRISPR-mediated cassette
- 247 exchange of the marked placeholder for the *doublesex* exon 5 variants. Injected survivors
- 248 (G0) were distinguished from non-injected survivors (G0), as they exhibited red fluorescence
- 249 in their posterior, due to successful injection of the p174104 CRISPR plasmid, containing a
- 250 DsRed cassette in its backbone, which acted as a co-injection marker (Supplementary 251 Figure 1D-E). All injected survivors (G0) were crossed to wild-type and females were
- 252 deposited to lay eggs individually. A decreased inheritance of the marked placeholder 253 (GFP+) in G1 progeny indicated CRISPR-mediated cassette exchange of the placeholder for 254 the variant sequence (Figure 2). 255
- 256 Molecular genotyping

257 258 Genomic DNA was extracted from queried individuals after they gave offspring, in single 259 samples, amplified using primers dsx-exon5-R4 (AACTTATCGGCATCAGTTGCG) and dsx-260 intron4-F1 (GTGAATTCCGTCAGCCAGCA) and sequenced using the dsx-exon5-R2 primer 261 (TGAATTCGTTTCACCAAACACAC), to decipher their genotype. 262

- 263 Analysis
- 264

265 Figures were designed on Biorender (full licence) and Adobe Illustrator and graphs were 266 plotted and statistically analysed on Graphpad Prism 9. 267

268 269

270 Results

271 272 We tested the efficiency of CriMCE and demonstrated proof of principle by using it to 273 engineer and isolate mutations that potentially confer resistance to a gene drive, previously developed against the doublesex (dsx) gene in the malaria mosquito, Anopheles gambiae.¹⁶ 274

- 275 276 First, we generated a placeholder strain by inserting a GFP cassette in place of the entire 277 female-specific exon (exon 5) of dsx via CRISPR-mediated HDR (Figure 2A). This strain 278 was isolated based on GFP fluorescence, and displayed an intersex phenotype in
- 279 homozygous females, consistent with the null mutation.¹⁶
- 280
- 281 We then performed CRISPR-mediated cassette exchange (CriMCE) of the placeholder for
- 282 the marker-less SNP of interest (G \rightarrow A, C \rightarrow T or G \rightarrow T), by injecting placeholder
- 283 homozygotes and heterozygotes with a plasmid expressing Cas9 and gRNAs targeted to the
- 284 placeholder, and a template for repair encoding the variant of interest (Supplementary
- 285 Figure 1D-E, 3B). To maximise the recovery of editing events, we selected only the fraction of injected mosquitoes that showed transient RFP fluorescence as clear evidence of having 286

taken up the CRISPR expression vector (Supplementary Figure 1D-E) and mated these to
 wild-type (Figure 3).

289

290 CriMCE-induced editing was evidenced by loss of GFP (<100% GFP inheritance) among the 291 offspring of placeholder homozygotes, or by significant deviation below the Mendelian 292 expectation of 50% GFP inheritance among the offspring of placeholder heterozygotes 293 (**Figure 3**). We saw rates of precise editing up to 39% for the $G \rightarrow A$ SNP (evidenced by 61%) 294 GFP inheritance in the offspring of placeholder homozygotes) (Figure 3A), up to 100% for 295 the C \rightarrow T SNP, and up to 92% for the G \rightarrow T SNP variant (evidenced by 0% and 4% GFP 296 inheritance in the offspring of placeholder heterozygotes, respectively) (Figure 3B). 297 Incorporation of the SNPs of interest was confirmed by Sanger sequencing (Supplementary 298 Figure 2). Notably, we did not detect any end-joining (EJ) events (N=55). Owing to the high 299 rates of editing by CriMCE, G1 transformants that showed low levels of GFP inheritance can 300 be immediately crossed to the placeholder strain that will act as a balancer, for rapid 301 characterisation of each marker-less edit. 302 303 In two G1 clutches with altered GFP inheritance we also detected variant donor plasmid

- In two G1 clutches with altered GFP inheritance we also detected variant donor plasmid
 integration, evidenced by RFP at 2% and 18% amongst GFP negatives (with a median of
 0% taken across all modified clutches) (Supplementary Figure 1). These were not
 considered as true transformants in our analysis (Table 1, Figure 4).
- 307

To compare our method to previously developed strategies employing HDR and prime editing to introduce and isolate marker-less edits,^{12,14,15} we calculated three measures of transformation efficiency: the percentage of G0 founders that gave G1 transformants, the G1 transformant to G0 injected survivor ratio, and the G1 transformant percentage out of all G1 screened (**Table 1**). If the G1 transformant to G0 injected survivor ratio is high, then a high number of transformants can be obtained from a smaller number of injected survivors; whilst

- having a high percentage of G1 transformants out of total G1 screened, implies a reduced
- 315 requirement for screening, whether this is done visually, like in the present study (less 316 laborious), or by PCR and sequencing analysis, like in previous studies (more laborious). As
- a reference, we also show the efficiency of locus-specific marked transgene insertion
 through RMCE and HDR (**Table 1**).
- 319

320 In total, we detected visible editing in the progeny of 7/18 (38.9%) G0 micro-injected

- individuals with the G \rightarrow A construct, 3/8 (37.5%) G0 micro-injected individuals with the C \rightarrow T construct, and 4/9 (44.4%) G0 micro-injected individuals with the G \rightarrow T construct (**Figure 3**, **Table 1**).
- CriMCE offers a marked improvement in transformation efficiency when compared to other approaches employed to introduce marker-less edits (**Figure 4**). Specifically, CriMCE shows a mean G1 transformant to G0 injected survivor ratio of 5.76 (± 2.37 s.d.), compared to 0.14 (± 0.10 s.d.) for direct HDR (Welch's t-test p=0.031) and 1.06 (± 0.83 s.d.) for prime editing; and a mean G1 transformant per G1 screened percentage of 10.5% ($\pm 6.0\%$ s.d.), compared to 1.0% ($\pm 0.5\%$ s.d.) for direct HDR and 1.4% ($\pm 1.1\%$ s.d.) for prime editing (Welch's t-test p=0.058) (**Figure 4**).
- 332 333

334 Discussion335

To address the difficulty in engineering and isolating marker-less edits in insects, we have

- developed a strategy based upon CRISPR-mediated cassette exchange (CriMCE) of a
- marked placeholder for a variant of interest, allowing visual detection of transformation.
- 339

340 Unlike other two-step methods for marked cassette exchange or removal, like recombinase-341 mediated cassette exchange (RMCE) and Cre-Lox recombination, CriMCE relies upon HDR. 342 This allows for comparatively high efficiency (when compared to RMCE) (Table 1), and 343 uniquely traceless editing such that any phenotypic change can be attributed to the intended 344 edit rather than ruminant attachment sites (Figure 1). Co-conversion of a target locus 345 together with a gene that produces a visual phenotype is another HDR-based strategy that 346 has been used to improve isolation of marker-less edits.²⁶ This filters individuals showing 347 CRISPR activity, however it does not distinguish HDR events that incorporate the desired 348 edit, from EJ events carrying unwanted indels.²⁶

349

350 Increasing the relative frequency of HDR over error-prone EJ repair remains difficult. Our

strategy leverages loss of a marked placeholder (GFP+) to indicate precise editing by HDR.
 By targeting CRISPR to non-coding regions of the placeholder, undesirable EJ events are
 screened out as they are unlikely to affect GFP expression. Furthermore, we express Cas9
 under the control of *zpg* regulatory elements that are spatiotemporally restricted to enhance

- HDR.²⁷ Indeed, no EJ mutations were detected in GFP- negative transformants. This
 focuses molecular identification by PCR and sequencing on individuals carrying the desired
 edit, therefore reducing the rearing effort required to enrich the frequency of marker-less
- 358 variants (**Supplementary Figure 3**).
- 359

Somewhat surprisingly, rates of HDR-induced editing are relatively high when marked 360 mutations are introduced (Table 1),^{23,28–30} but drop substantially when SNPs are directly 361 362 inserted into a wild-type genomic locus, in Aedes aegypti and An. gambiae (Table 1, Figure 363 4).^{14,15} Using CriMCE in An. gambiae we achieved high rates of HDR editing consistent with those for marked edit insertion in An. gambiae and D. melanogaster (Table 1, Figure 4).28,29 364 In both cases, repair templates differ significantly from their target regions: transgenes 365 366 introduced via HDR do not resemble their genomic target, while in the present study the 367 wild-type target is replaced by a placeholder, which serves to differentiate it from the desired 368 edit (Figure 2). Conversely, when direct HDR is used to induce small marker-less edits the 369 repair template is almost identical to that of the wild-type target. It is still unclear why 370 sequence dissimilarity between the exogenous repair template and its target should boost 371 the efficiency of editing, but perhaps it functions to shift repair away from using the 372 unmodified homologous chromosome as a template. Non-plasmid-based templates could 373 also be used in a CriMCE strategy, such as single-stranded oligodeoxynucleotide (ssODN) 374 that are simpler to produce and might further increase the rates of editing.³¹

375

376 CriMCE might be less efficient in species with inherently low rates of HDR, such as *An.*377 *stephensi* (**Table 1**),^{20,23} and alternatives not reliant upon HDR, like base and prime editing,¹¹
378 have not yet been tested in non-model insects. In these species, CriMCE can be optimised
379 by injecting placeholder homozygotes, so that rare events are distinguished by visual
380 inspection alone (**Figure 3A**).

381

The CriMCE method can also mitigate against the risk of using previously untested and potentially inefficient gRNAs/pegRNAs that would otherwise expend undue effort on genetic crosses and molecular genotyping. Generating a marked placeholder prior to precise editing ensures that rare transgenesis using novel gRNA/pegRNAs is easily identifiable by a fluorescent marker. Previously tested guides can then be used to target the placeholder, inducing CriMCE. In this study we validate the use of two gRNAs that target a universal placeholder which is designed to function across insect species.

389

390 CriMCE is particularly powerful for experiments aimed at introducing a range of modifications 391 to a single locus of interest, as a single placeholder strain can be exchanged for any number

- 392 of variants. Indeed, a similar approach, based upon exchange of a marked allele for
- 393 engineering of *kdr* pyrethroid resistance mutations was employed in *Drosophila*,³² and could
- 394 be further extended to incorporate newly discovered insecticide resistant SNPs.³³

395

396 Moreover, CriMCE allows for complex mutations that are not possible using prime editing since the entire region ablated by the placeholder can be replaced with a region bearing any 397 398 number of desired edits. This strategy, which we term allelic exchange (Figure 1C), could 399 allow multiple linked SNPs to be introduced across a wide genetic locus. This would be 400 useful in assessing how various resistant SNPs interact with each other to produce complex 401 insecticide resistance phenotypes.⁴ Other complex edits are also possible such as the 402 introduction, modification or deletion of introns and splice site, or complete codon scrambling 403 by which a coding sequence is modified without affecting the encoded amino acid sequence 404 (Figure 1C). The latter strategy could serve to engineer synthetic alleles that are resistant to 405 gene drive elements as a mechanism for gene drive recall.³⁴ 406 407 Finally, we describe how CriMCE can be used to target haploinsufficient genes, which by

- 408 their nature, would be unable to tolerate a disruption from the placeholder, even if the
- 409 desired edit is anticipated to be viable. In this case, integrating the placeholder within
- 410 proximal intronic or neutral regions should permit editing (Supplementary Figure 4).
- 411 412

413 Conclusions

414

415 CriMCE is an efficient method to introduce and isolate precise and potentially complex 416 marker-less edits by exchange of a visually marked intermediate. Our proof-of-principle 417 experiments in *Anopheles gambiae* suggest that CriMCE is 5-41x more efficient than other 418 strategies based on HDR or prime editing, whilst enabling an expanded range of potential 419 addite and especification the workflow. In our experiments the use of a placeholder strain door

edits and consolidating the workflow. In our experience the use of a placeholder strain does
 not prolong isolation of the desired edit and can be used as an important control or balancer

in assessing its phenotype. We believe this strategy will be important in linking small geneticchanges with a biologically relevant outcome across a range of insect species, with

- 423 particular applications in the study of resistance to insecticides and gene drive technologies.
 424
- 425 426

427 Acknowledgements

We thank Louise Marston, Matthew Gribble and Molly McGrath for their help towards
generating and maintaining transgenic strains.

431

432 433

434 Author contribution statement

The idea was conceived by I.M., A.C. and A.M.H. The experiments were designed by I.M.
with input from T.N. and A.M.H. The experiments, data visualisation and analysis were
performed by I.M. The original draft was written by I.M. and edited by A.M.H. The manuscript
was reviewed by all authors.

- 440
- 441 442

443 Conflict of interest statement444

445 A.C. and A.M.H. are founders of Biocentis, Ltd. A.C., T.N. and A.M.H. have an equity 446 interest in Biocentis, Ltd. I.M. declares no conflict of interest.

- 447 448
- 449

450

451 **Funding statement**

452

This work was supported by funding from a Medical Research Council (MRC) Doctoral
Training Partnership (DTP) and grants from the Bill & Melinda Gates Foundation (BMGF).
Funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.

457 458

459 **References**

- 460
 461 1. Wang Z and Moult J. SNPs, Protein Structure, and Disease. Human Mutation
 462 2001;17(4):263–270; doi: 10.1002/humu.22.
- 463
 463
 464
 464
 464
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
- 466 3. Hemingway J and Ranson H. Insecticide Resistance in Insect Vectors of Human
 467 Disease. Annu Rev Entomol 2000;45:371–391; doi: 10.1146/annurev.ento.45.1.371.
- 468
 4. Samantsidis GR, Panteleri R, Denecke S, et al. 'What I Cannot Create, I Do Not Understand': Functionally Validated Synergism of Metabolic and Target Site Insecticide Resistance. Proceedings of the Royal Society B: Biological Sciences 2020;287(1927); doi: 10.1098/rspb.2020.0838.
- 472 5. Hsu PD, Lander ES and Zhang F. Development and Applications of CRISPR-Cas9 for 473 Genome Engineering. Cell 2014;157(6):1262–1278; doi: 10.1016/j.cell.2014.05.010.
- 474 6. Petri K, Zhang W, Ma J, et al. CRISPR Prime Editing with Ribonucleoprotein
 475 Complexes in Zebrafish and Primary Human Cells. Nature Biotechnology 2021
 476 2021;1–5; doi: 10.1038/s41587-021-00901-y.
- 477 7. Lin Q, Jin S, Zong Y, et al. High-Efficiency Prime Editing with Optimized, Paired
 478 PegRNAs in Plants. Nature Biotechnology 2021 39:8 2021;39(8):923–927; doi:
 479 10.1038/s41587-021-00868-w.
- 4808.Villiger L, Grisch-Chan HM, Lindsay H, et al. Treatment of a Metabolic Liver Disease481by in Vivo Genome Base Editing in Adult Mice. Nature Medicine 2018 24:104822018;24(10):1519–1525; doi: 10.1038/s41591-018-0209-1.
- 483
 483
 484
 484
 485
 485
 486
 487
 487
 488
 488
 489
 480
 480
 480
 480
 480
 480
 481
 481
 481
 482
 482
 483
 483
 484
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
 485
- Li C, Zong Y, Wang Y, et al. Expanded Base Editing in Rice and Wheat Using a
 Cas9-Adenosine Deaminase Fusion. Genome Biology 2018;19(1):1–9; doi:
 10.1186/S13059-018-1443-z.
- 489 11. Anzalone A v., Koblan LW and Liu DR. Genome Editing with CRISPR–Cas
 490 Nucleases, Base Editors, Transposases and Prime Editors. Nature Biotechnology
 491 2020 38:7 2020;38(7):824–844; doi: 10.1038/s41587-020-0561-9.
- 492 12. Bosch JA, Birchak G and Perrimon N. Precise Genome Engineering in Drosophila
 493 Using Prime Editing. Proc Natl Acad Sci U S A 2020;118(1); doi:
 494 10.1073/pnas.2021996118.
- 495 13. Marr E and Potter CJ. Base Editing of Somatic Cells Using CRISPR-Cas9 in
 496 Drosophila. CRISPR Journal 2021;4(6):836–845; doi: 10.1089/crispr.2021.0062
- 497 14. Grigoraki L, Cowlishaw R, Nolan T, et al. CRISPR/Cas9 Modified An. Gambiae
 498 Carrying Kdr Mutation L1014F Functionally Validate Its Contribution in Insecticide
 499 Resistance and Combined Effect with Metabolic Enzymes. PLOS Genetics
 500 2021;17(7):e1009556; doi: 10.1371/journal.pgen.1009556.
- 50115.Kistler KE, Vosshall LB and Matthews BJ. Genome Engineering with CRISPR-Cas9 in
the Mosquito Aedes Aegypti. Cell Rep 2015;11(1):51–60; doi:
- 503 10.1016/j.celrep.2015.03.009.

504 16. Kvrou K. Hammond AM. Galizi R. et al. A CRISPR-Cas9 Gene Drive Targeting 505 Doublesex Causes Complete Population Suppression in Caged Anopheles Gambiae 506 Mosquitoes. Nature Biotechnology 2018; doi: 10.1038/nbt.4245. 507 17. Morianou I, Hammond AM, Crisanti A, et al. In Preparation. London; 2022. 508 Hammond A, Pollegioni P, Persampieri T, et al. Gene-Drive Suppression of Mosquito 18. 509 Populations in Large Cages as a Bridge between Lab and Field. Nature 510 Communications 2021 12:1 2021;12(1):1–9; doi: 10.1038/s41467-021-24790-6. 511 19. Carballar-Lejarazú R, Ogaugwu C, Tushar T, et al. Next-Generation Gene Drive for 512 Population Modification of the Malaria Vector Mosquito, Anopheles Gambiae. Proc 513 Natl Acad Sci U S A 2020;117(37):22805-22814; doi: 10.1073/pnas.2010214117. 514 20. Adolfi A, Gantz VM, Jasinskiene N, et al. Efficient Population Modification Gene-Drive 515 Rescue System in the Malaria Mosquito Anopheles Stephensi. Nature 516 Communications 2020 11:1 2020;11(1):1-13; doi: 10.1038/s41467-020-19426-0. 517 Hammond AM, Kyrou K, Bruttini M, et al. The Creation and Selection of Mutations 21. 518 Resistant to a Gene Drive over Multiple Generations in the Malaria Mosquito. PLoS 519 Genetics 2017; doi: 10.1371/journal.pgen.1007039. 520 22. Carrami EM, Eckermann KN, Ahmed HMM, et al. Consequences of Resistance 521 Evolution in a Cas9-Based Sex Conversion-Suppression Gene Drive for Insect Pest 522 Management. Proc Natl Acad Sci U S A 2018;115(24):6189-6194; doi: 523 10.1073/pnas.1713825115. 23. 524 Gantz VM, Jasinskiene N, Tatarenkova O, et al. Highly Efficient Cas9-Mediated Gene 525 Drive for Population Modification of the Malaria Vector Mosquito Anopheles 526 Stephensi. Proc Natl Acad Sci U S A 2015;112(49):E6736-E6743; doi: 527 10.1073/pnas.1521077112. 528 Fuchs S, Nolan T and Crisanti A. Mosquito Transgenic Technologies to Reduce 24. 529 Plasmodium Transmission. Methods Mol Biol 2013;923:601-622; doi: 10.1007/978-1-530 62703-026-7 41. 531 25. Marois E, Scali C, Soichot J, et al. High-Throughput Sorting of Mosquito Larvae for 532 Laboratory Studies and for Future Vector Control Interventions. Malaria Journal 2012; 533 doi: 10.1186/1475-2875-11-302. 534 26. Tianfang Ge D, Tipping C, Brodsky MH, et al. Rapid Screening for CRISPR-Directed 535 Editing of Th Drosophila Genome Using White Coconversion. G3: Genes, Genomes, 536 Genetics 2016;6(10):3197-3206; doi: 10.1534/G3.116.032557. 537 Hammond A, Karlsson X, Morianou I, et al. Regulating the Expression of Gene Drives 27. 538 Is Key to Increasing Their Invasive Potential and the Mitigation of Resistance. PLOS 539 Genetics 2021;17(1):e1009321; doi: 10.1371/journal.pgen.1009321. 540 28. Hammond A, Galizi R, Kyrou K, et al. A CRISPR-Cas9 Gene Drive System Targeting 541 Female Reproduction in the Malaria Mosquito Vector Anopheles Gambiae. Nature 542 Biotechnology 2016; doi: 10.1038/nbt.3439. 543 29. Gratz SJ, Ukken FP, Rubinstein CD, et al. Highly Specific and Efficient 544 CRISPR/Cas9-Catalyzed Homology-Directed Repair in Drosophila. Genetics 545 2014;196(4):961-971; doi: 10.1534/genetics.113.160713. 546 30. Ang JX de, Nevard K, Ireland R, et al. Considerations for Homology-Based DNA 547 Repair in Mosquitoes: Impact of Sequence Heterology and Donor Template Source. 548 PLOS Genetics 2022;18(2):e1010060; doi: 10.1371/journal.pgen.1010060. 549 Levi T, Sloutskin A, Kalifa R, et al. Efficient in Vivo Introduction of Point Mutations 31. 550 Using SsODN and a Co-CRISPR Approach. Biological Procedures Online 2020;22(1):1-12; doi: 10.1186/S12575-020-00123-7. 551 552 Kaduskar B, Kushwah RBS, Auradkar A, et al. Reversing Insecticide Resistance with 32. 553 Allelic-Drive in Drosophila Melanogaster. Nature Communications 2022 13:1 554 2022;13(1):1-8; doi: 10.1038/s41467-021-27654-1. 555 33. Clarkson CS, Miles A, Harding NJ, et al. The Genetic Architecture of Target-Site 556 Resistance to Pyrethroid Insecticides in the African Malaria Vectors Anopheles 557 Gambiae and Anopheles Coluzzii. Molecular Ecology 2021;30(21):5303-5317; doi: 558 10.1111/mec.15845.

- 55934.Vella MR, Gunning CE, Lloyd AL, et al. Evaluating Strategies for Reversing CRISPR-560Cas9 Gene Drives. Scientific Reports 2017 7:1 2017;7(1):1–8; doi: 10.1038/s41598-
- 561 017-10633-2.

562

Figure 1. CRISPR-mediated cassette exchange (CriMCE) is a two-step method for engineering the detection and isolation of marker-less edits via CRISPR-mediated homology-directed repair. (A) Step 1: To generate a marked placeholder strain, the region of interest (gene B) is replaced by a marker (GFP, green). Step 2: The marker is replaced by the native sequence containing the variant of interest (orange), through CRISPR-mediated cassette exchange (CriMCE), to obtain a marker-less strain carrying the variant. (B) Examples of the types of simple and complex genetic modifications that can be obtained using CriMCE. (C) Comparison of CriMCE to other methods used to make precise genomic edits, including recombinase mediated cassette exchange (RMCE), direct homology-directed repair (HDR) of a wild-type sequence and base or prime editing.

Figure 2. CriMCE relies upon the generation of a marked placeholder strain, and the subsequent exchange of the placeholder for the variant of interest through CRISPR-mediated HDR. (A) To generate the marked placeholder strain, the entirety of the exon 5 coding sequence (CDS) was removed via two CRISPR-mediated double-stranded breaks (DSBs) and replaced with a 3xP3::GFP::SV40 marker cassette (green) from a donor plasmid that served as a template for HDR. (B) To generate a strain carrying the variant of choice (G \rightarrow A, C \rightarrow T or G \rightarrow T SNPs at exon 5) the marker cassette was removed via two CRISPR-mediated cleavages and exchanged for the exon 5 CDS containing the variant of interest (orange) from a donor plasmid, through HDR.

Figure 3. The introduction of a marker-less variant using CriMCE is evidenced by reduced rates of marker inheritance in the progeny of microinjected individuals of the placeholder strain. Marked placeholder male homozygotes (A) and heterozygotes of both sexes (B), were microinjected with a CRISPR helper plasmid and a variant donor plasmid to facilitate CriMCE of the placeholder for one of the variants of interest ($G \rightarrow A, C \rightarrow T, G \rightarrow T$). G0 parent injected mosquitoes (green) were individually crossed to wild-type (grey) and their G1 progeny screened for GFP fluorescence. Successful introduction of each marker-less variant via CriMCE, was evidenced by a marker frequency of less than 100% in the progeny of placeholder heterozygotes (orange). Lack of modification was evidenced by a marker frequency normally distributed around 50% in the progeny of placeholder heterozygotes (green).

Figure 4. Comparison of CriMCE to different transgenesis methods for the introduction of small precise marker-less edits. Welch's t-test p-values of statistical comparisons between CriMCE and prime editing are shown on top of each graph. HDR could not be statistically compared due to its small sample size.

Supplementary Figure 1. A cloning strategy to create variant donor plasmids and graphical representation of all microinjected plasmids required to facilitate CriMCE. (A) The donor plasmid precursor contains *Bsal* sites (turquoise) flanked by homology arms complementary to the regions upstream and downstream of the target locus. Through Golden Gate cloning, any variant of interest (orange) can be inserted between the Bsal cloning sites, whilst they get removed leaving no molecular trace behind. (B-C) To create a variant donor plasmid (using the $G \rightarrow A$ SNP as an example), Bsal recognition sites were introduced upstream and downstream of the 23 bp locus of interest on exon 5. Bsal recognition and cleavage sites are distinct, therefore they are placed facing outwards in the donor precursor sequence, to ensure that upon cleavage they get lost, exposing staggered DNA ends on the plasmid precursor. A fragment containing the $G \rightarrow A$ variant and complementary staggered DNA ends can then be ligated onto the plasmid precursor to make-up the final variant donor plasmid. (D) Co-injected plasmids used to generate the marked placeholder strain. (E) Co-injected plasmids used to generate the variant strains. (D-E) CRISPR plasmids, marked by DsRed (top), express Cas9 under the control of the germline-specific zpg regulatory elements, along with two gRNAs under the control of ubiquitous U6 promoters and targeted to the dsx exon 5 (D, T1 and T3) or the placeholder cassette (E, G1 and G2). Donor plasmids for HDR (bottom), were designed to contain either the placeholder GFP cassette (D, green) or the dsx exon 5 bearing the variant of interest (E, orange), flanked by 1.8 kb homology arms complementary to the target region in *doublesex*. Donor plasmid backbones were marked by DsRed.

Supplementary Figure 2. Molecular validation of successful CriMCE-induced genetic modification through Sanger sequencing. Sanger sequencing chromatographs from single GFP- mosquitoes. Top: WT, example of an unedited individual. Middle: example of a heterozygous edited individual carrying the SNP variant of interest ($G \rightarrow A$, $C \rightarrow T$ or $G \rightarrow T$), evident through a double peak in the chromatograph. Bottom: example of a homozygous edited individual carrying the SNP variant of interest in homozygosis ($G \rightarrow A$, $C \rightarrow T$ or $G \rightarrow T$), evident through a single modified peak in the chromatograph. Note that reverse strand sequencing chromatographs are shown.

Supplementary Figure 3. An illustration of the workflow required to isolate a homozygous variant strain when employing CriMCE vs HDR or prime editing for the introduction of precise marker-less edits. Wild-type mosquitoes are in grey, unmodified mosquitoes in black, placeholder mosquitoes in green, variant heterozygotes in orange, and variant homozygotes in red.

Supplementary Figure 4. A strategy for introducing precise marker-less edits into haploinsufficient genes using CriMCE. CriMCE can be adapted to modify haploinsufficient genes by introducing the marked placeholder into a neutral locus, like an intron, proximal to a target site on a haploinsufficient exon. (A) To generate a marked placeholder strain, a highly variable intronic region, proximal to the haplo-insufficient exon, is cleaved using CRISPR, and a marker cassette (red) is introduced from a donor plasmid, through HDR. (B) To generate a strain carrying the variant of choice on the exon the marker cassette is removed via two CRISPR-mediated cleavages: one at the marker cassette and one near the site of interest; and exchanged for an intact sequence containing the variant of choice from a donor plasmid, through HDR. The same strategy could be adopted to allow exclusive microinjection of placeholder homozygotes, provided that the intronic placeholder integration is tolerated in both males and females, to improve CriMCE efficiency in organisms that show inherently low HDR.



| С | Visual identification | Scarless strain | Type of modification | Transgenesis steps | Generations to homozygosis (N) | Rearing effort | Generations sequenced |
|-----------------------|-----------------------|--------------------|----------------------|-----------------------|-----------------------------------|-------------------|--------------------------|
| CriMCE | \checkmark | \checkmark | Simple & complex | 2 | 3 | medium | 1-2 |
| RMCE | \checkmark | × | Simple & Complex | 2 | 3 | medium | 1-2 |
| HDR | × | \checkmark | Simple & Complex | 1 | 4 | very high | 3-4 |
| base/prime editing | × | \checkmark | Simple | 1 | 4 | very high | 3-4 |







Table 1. Comparison of CriMCE to different transgenesis methods for the introduction of small precise marker-less edits or marked transgenes. Efficiency of each method is measured through the G1 transformant to G0 injected survivor ratio and the % of G1 transformants isolated from screened G1 progeny.

| Transgenesis method and study | | Organism | Eggs injected N | G0 Injected survivors N | G1 transformants N | Total G1 screened N | G0 Founders N (%) | G1 transformant to G0 injected survivor ratio | G1 transformants per G1 screened % | |
|---|--------------------------------------|--------------------|----------------------------|----------------------------------|--------------------------|---------------------------|----------------------|--|---|-------|
| | | | | | Introduction | of precise marke | r-less edit | | | |
| CriMCE present study | G | ->A | Anopheles gambiae | 380 | 18* (59) | 111*+ | 1716 | 7/18 (38.9) | 6.17 | 6.47 |
| | С | ->T | Anopheles gambiae | 1025 | 21 | 166*+ | 953 | 3/8 (37.5) | 7.90 | 17.42 |
| | G->T | | Anopheles gambiae | 963 | 23 | 74++ | 97 | 4/9 (44.4) | 3.22 | 7.62 |
| HDR | Kistler et al. (2015) | | Aedes aegypti | 636 | 61** | 4** | 620 | N/A | 0.07 | 0.65 |
| | Grigoraki et al. (2021) | | Anopheles gambiae | 338 | 19 | 4** | 290 | 1/19 (5.0) | 0.21 | 1.38 |
| Prime Editing Bosch et al. (2021)*** | Plasmid pegRNA | | Drosophila melanogaster | 50 | 18 | 3** | 1767 | 1/18 (5.6) | 0.17 | 0.17 |
| | Plasmid pegRNA+ sgRNA | | Drosophila melanogaster | 50 | 15 | 28** | 1594 | 6/15 (40.0) | 1.20 | 1.76 |
| | Synthetic pegRNA | | Drosophila melanogaster | 50 | 11 | 20** | 866 | 4/9 (44.4) | 1.82 | 2.31 |
| Introduction of marked transgene | | | | | | | | | | |
| RMCE Hammond et al. (2016) | 7280 | | Anopheles gambiae | 540 | 56** | 15⁺ | 4000 | N/A | N/A | 0.38 |
| | 11377 | | Anopheles gambiae | 500 | 21** | 4* | 2990 | N/A | N/A | 0.13 |
| | 5958 | | Anopheles gambiae | 400 | 49** | 2* | 4000 | N/A | N/A | 0.05 |
| HDR | Gratz et al. (2014) | | Drosophila melanogaster | N/A | 50 | 599+ | 7657 | 9/50 (18.0) | 11.98 | 7.82 |
| | Gantz et al. (2015) ⁺⁺ | | Anopheles stephensi | 680 | 251** | 2* | 25,712 | N/A | 0.01 | 0.01 |
| | mond (2016) | 7280 | Anopheles gambiae | 350 | 48 | 278* | 1536 | 9/48 (18.8) | 5.79 | 18.10 |
| | Ham et al. | 5958 | Anopheles gambiae | 760 | 26 | 51* | 3184 | 3/26 (11.5) | 1.96 | 1.60 |
| | Adolfi et al. (2020) | | Anopheles stephensi | 504 | 184** | 96* | 25,293 | N/A | 0.52 | 0.38 |
| | Ang et al. (2022) | 190- perfect | Aedes aegypti | N/A | 271** | 350 | 9,774 | 13/13 (100.0)º | 1.29 | 3.6 |
| | | 64+234- perfect | Aedes aegypti | N/A | 355** | 207 | 22,158 | 8/17 (47.1)° | 0.58 | 0.93 |

*Only 18 out of 59 G0 injected survivors were kept and crossed to obtain G1 transgenics, due to Covid-19 restrictions in April 2020.

**In most studies G0 injected survivors are not being distinguished from non-injected survivors through transient expression of a fluorescent marker. The Kistler et al. (2015), Gantz et al. (2015), Hammond et al. (2016), Adolfi et al. (2020) and Ang et al. (2022) studies did not use such a method to distinguish injected survivors, or used all injected survivors (whether or not they showed signs of injection) to obtain transgenics.

***Showing the set of injections with greater success for each method of prime editing: (a) using pegRNA expressed from a plasmid to provide cleavage and a template for repair, (b) using plasmid pegRNA together with an sgRNA to provide cleavage, (c) injecting a synthetic pegRNA straight away.

+Identified visually.

**Identified through sequencing.

+The number of transformants is equal to the number of individuals lacking a fluorescent marker in the progeny of placeholder homozygotes. The number of transformant in the progeny of placeholder heterozygotes it was estimated using this formula: (Total G1)/2 - GFP⁺ - RFP⁺. ⁺⁺Note that the transgene integrated by HDR in the Gantz et al. (2015) study was significantly larger in size

compared to all other studies, which could have reduced efficiency of integration. ^oThe number of G0 founder pools that gave G1 transformants out of total G0 survivor pools is shown.

| Transgenesis method and study | | Organism | Eggs injected N | G0 Injected survivors N | G1 transformants N | Total G1 screened N | G0 Founders N (%) | G1 transformant to G0 injected survivor ratio | G1 transformants per G1 screened % | |
|--|--------------------------------------|--------------------|----------------------------|----------------------------------|--------------------------|---------------------------|----------------------|--|---|-------|
| Introduction of precise marker-less edit | | | | | | | | | | |
| CriMCE present study | G->A | | Anopheles gambiae | 380 | 18* (59) | 111*+ | 1716 | 7/18 (38.9) | 6.17 | 6.47 |
| | C->T | | Anopheles gambiae | 1025 | 21 | 166 * + | 953 | 3/8 (37.5) | 7.90 | 17.42 |
| | G->T | | Anopheles gambiae | 963 | 23 | 74 * + | 97 | 4/9 (44.4) | 3.22 | 7.62 |
| HDR - | Kistler et al. (2015) | | Aedes aegypti | 636 | 61** | 4** | 620 | N/A | 0.07 | 0.65 |
| | Grigora (20 | aki et al. 021) | Anopheles gambiae | 338 | 19 | 4** | 290 | 1/19 (5.0) | 0.21 | 1.38 |
| Prime Editing Bosch et al. (2021)*** | Plasmid pegRNA | | Drosophila melanogaster | 50 | 18 | 3** | 1767 | 1/18 (5.6) | 0.17 | 0.17 |
| | Plasmid pegRNA+ sgRNA | | Drosophila melanogaster | 50 | 15 | 28** | 1594 | 6/15 (40.0) | 1.20 | 1.76 |
| | Synthetic pegRNA | | Drosophila melanogaster | 50 | 11 | 20** | 866 | 4/9 (44.4) | 1.82 | 2.31 |
| Introduction of marked transgene | | | | | | | | | | |
| RMCE Hammond et al. (2016) | 7280 | | Anopheles gambiae | 540 | 56** | 15* | 4000 | N/A | N/A | 0.38 |
| | 11377 | | Anopheles gambiae | 500 | 21** | 4* | 2990 | N/A | N/A | 0.13 |
| | 5958 | | Anopheles gambiae | 400 | 49** | 2* | 4000 | N/A | N/A | 0.05 |
| | Gratz et al. (2014) | | Drosophila melanogaster | N/A | 50 | 599 ⁺ | 7657 | 9/50 (18.0) | 11.98 | 7.82 |
| | Gantz et al. (2015) ^{+∔} | | Anopheles stephensi | 680 | 251** | 2* | 25,712 | N/A | 0.01 | 0.01 |
| | Hammond et al. (2016) | 7280 | Anopheles gambiae | 350 | 48 | 278* | 1536 | 9/48 (18.8) | 5.79 | 18.10 |
| | | 5958 | Anopheles gambiae | 760 | 26 | 51* | 3184 | 3/26 (11.5) | 1.96 | 1.60 |
| | Adolfi et al. (2020) | | Anopheles stephensi | 504 | 184** | 96* | 25,293 | N/A | 0.52 | 0.38 |
| | Ang et al. (2022) | 190- perfect | Aedes aegypti | N/A | 271** | 350 | 9,774 | 13/13 (100.0)° | 1.29 | 3.6 |
| | | 64+234- perfect | Aedes aegypti | N/A | 355** | 207 | 22,158 | 8/17 (47.1)° | 0.58 | 0.93 |



Reverse strand Sanger sequencing reads:





